Chengda Pharmaceuticals Co (SZSE:301201) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301201 Chengda Pharmaceuticals Co Ltd SZSE:301201
75 GF Score
Price ¥37.94
GF Value ¥30.45
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengda Pharmaceuticals Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Chengda Pharmaceuticals Co Valuation Rank Related Terms

SZSE:301201
75GF Score
Chengda Pharmaceuticals Co Ltd SZSE:301201
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?

Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued. The current stock price of ¥37.94 is trading 24.6% above its estimated GF Value™ of ¥30.45. GuruFocus considers Chengda Pharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for SZSE:301201:

  • Valuation Rank:
  • GF Value™: ¥30.45 vs. price of ¥37.94 (24.6% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengda Pharmaceuticals Co Business Description

Address 36 Huanghe Road, Huimin Street, Jiashan County, Zhejiang Province, Jiaxing, CHN, 314100
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score

Get the complete analysis for SZSE:301201

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥37.94
Price
¥30.45
GF Value